secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0001104659-25-079880
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics files prospectus supplement for up to $80M ATM stock offering
--------------------------------------------------------------------------------

- Filed prospectus supplement to sell up to $80M of common stock via ATM program with Canaccord Genuity.
- ATM program established April 3, 2025; supplement filed August 18, 2025.
- Honigman LLP issued validity opinion on shares; counsel's opinion filed as Exhibit 5.1.
- Shares to be sold through any method deemed an 'at the market' offering under Rule 415(a)(4).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925079880/0001104659-25-079880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925079880/tm2523368d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-079880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer